NGeneBio Co

NGeneBio Co R&D per Employee

The R&D Spending per Employee of NGeneBio Co (354200.KQ) as of Nov 19, 2026 is 13.41 M KRW. In the previous year, R&D Spending per Employee was 22.62 M KRW — a change of -40.74% (lower).

R&D per Employee

13.41 MKRW

YoY

-40.74%

Last updated:

R&D Spending per Employee of NGeneBio Co is 2025 13.41 M KRW. R&D Spending per Employee of NGeneBio Co was 2024 22.62 M KRW. It decreases by -40.74% lower compared to the previous year.

The NGeneBio Co R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2019
21.23 M KRW
Jan 1, 2020
25.94 M KRW
Jan 1, 2021
35.94 M KRW
Jan 1, 2022
36.97 M KRW
Jan 1, 2023
36.33 M KRW
Jan 1, 2024
22.62 M KRW
Jan 1, 2025
13.41 M KRW
The NGeneBio Co R&D per Employee history
YEARR&D per EmployeeYoY
13.41 MKRW-40.74%
22.62 MKRW-37.73%
36.33 MKRW-1.72%
36.97 MKRW+2.87%
35.94 MKRW+38.54%
25.94 MKRW+22.16%
21.23 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NGeneBio Co Stock analysis

What does NGeneBio Co do? NGeneBio Co., Ltd. generates revenue through the development and sale of diagnostic products for cancer-related genetic testing. The company offers BRCAaccuTest for hereditary breast and ovarian cancer, HEMEaccuTest for blood cancer gene testing including leukemia and lymphoma, and SOLIDaccuTest for solid cancer tissues like lung and colon cancer. Additional products include HLAaccuTest for bone marrow transplantation antigen testing, ONCOaccuPanel for large-capacity solid cancer diagnosis, and HEREDaccuTest for rare disease diagnosis. The firm also provides direct-to-consumer genetic testing and personalized healthcare services, targeting healthcare providers, hospitals, and individual consumers seeking genetic insights. The company's product portfolio serves medical institutions and patients requiring precise genetic diagnostics. HEMEaccuTest specifically addresses blood cancer types such as leukemia and lymphoma, while SOLIDaccuTest covers common solid cancers including lung and stomach cancer. ONCOaccuPanel supports comprehensive solid cancer diagnosis, and HEREDaccuTest caters to rare disease diagnostics. These products are sold to healthcare facilities and offered directly to consumers through DTC services. NGeneBio's revenue streams include sales of diagnostic kits and services, with a focus on cancer-related genetic testing. The BRCAaccuTest, HEMEaccuTest, and SOLIDaccuTest products are central to its business, targeting both clinical and direct consumer markets. Personalized healthcare services complement the product offerings, enhancing customer engagement and recurring revenue opportunities. NGeneBio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NGeneBio Co stock

R&D Spending per Employee of NGeneBio Co is 13.41 M KRW in 2025.

R&D Spending per Employee of NGeneBio Co changed from 22.62 M KRW to 13.41 M KRW, representing a -40.74% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee NGeneBio Co since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's NGeneBio Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — NGeneBio Co

All Key Metrics — NGeneBio Co